ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
October 28, 2024 08:00 ET
|
ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
October 28, 2024 03:00 ET
|
ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
Qinotto and Lilly Enter Research Collaboration and License Agreement
October 08, 2024 12:00 ET
|
Qinotto Inc
SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule...
Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases
November 01, 2023 03:00 ET
|
Sitryx Therapeutics
Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...
World Leaders in Proteomics and Genomics to Convene at the 2nd International Top-Down Proteomics Symposium
September 20, 2023 11:11 ET
|
Consortium for Top-Down Proteomics
Building the bridge from genotype to phenotype, the Symposium will feature scientific leaders creating cutting edge technologies and approaches that are ushering in the era of proteoform systems...
The Consortium for Top-Down Proteomics Announces the 2nd International Top-Down Proteomics Symposium, October 3-5, 2023, in Chicago, IL
March 01, 2023 10:17 ET
|
Consortium for Top-Down Proteomics
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- The Consortium for Top-Down Proteomics today announced the 2nd International Top-Down Proteomics Symposium, which will be held in Chicago, IL...
Lilly and ProQR to Expand RNA Editing Collaboration
December 22, 2022 06:00 ET
|
ProQR Therapeutics N.V.
INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion...
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
September 08, 2021 16:01 ET
|
ProQR Therapeutics N.V.
Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA editing platformProQR to receive $50 million consisting of upfront...
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
July 08, 2020 10:00 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
IBRI Drives New Collaboration Model Targeting Type 2 Diabetes
December 22, 2016 11:45 ET
|
Indiana Biosciences Research Institute
INDIANAPOLIS, Ind., Dec. 22, 2016 (GLOBE NEWSWIRE) -- The Indiana Biosciences Research Institute (IBRI) today announced a new collaboration with Eli Lilly and Company, Roche Diagnostics, the...